The Centers for Disease Control and Prevention (CDC) issued an advisory concerning suspected Monkeypox-like infections in persons having contact with Prairie Dogs in Wisconsin, Illinois and Indiana. The Delaware Division of Public Health (DPH) provides the following additional information:
While unlikely, the possibility does apparently exist that Delaware residents may have recently purchased a Prairie Dog in Delaware. Prairie Dogs may also have been obtained by Delaware residents from other states. Therefore, DPH continues to monitor this situation closely. Questions or reports related to Monkeypox and Prairie Dogs should be directed to DPH at 888-295-5156. The CDC Advisory issued on June 7 is below.
An extensive multidisciplinary investigation in Wisconsin, Illinois and Indiana has identified cases of febrile rash illness in persons who had direct or close contact with recently purchased ill prairie dogs. Scientists at the Marshfield Clinic in Marshfield, Wisconsin, recovered viral isolates from a patient and a prairie dog and demonstrated a virus morphologically consistent with a poxvirus by electron microscopy (see http://research.marshfieldclinic.org/crc/prairiedog.asp for electron microscopy images).
Preliminary results of serologic testing and polymerase chain reaction testing of patients' specimens performed at the Centers for Disease Control and Prevention (CDC) on June 6-7 suggest that the causative agent is most closely related to monkeypox virus, a member of the orthopoxvirus family of viruses. Results of additional evaluation at CDC by electron microscopy and immunohistochemical studies are consistent with the finding of an orthopoxvirus. These findings represent the first evidence of community-acquired monkeypox-like infection in the United States. Further characterization of the virus is in progress.
Human monkeypox is a rare zoonotic viral disease that occurs primarily in the rain forest countries of central and west Africa. In humans, the illness produces a vesicular and pustular rash similar to that of smallpox. Limited person-to-person spread of infection has been reported in disease-endemic areas in Africa; the incubation period is about 12 days. Case-fatality ratios in Africa have ranged from 1% to 10% (for additional information about monkeypox, see http://www.cdc.gov/ncidod/eid/vol7no3/hutinG1.htm).
In the current U.S. outbreak, cases have been reported among residents of Wisconsin (17), northern Illinois (1), and northwestern Indiana (1). Onset of illness among patients began in early May. Patients typically experienced a prodrome consisting of fever, headaches, myalgias, chills and drenching sweats. Roughly one-third of patients had nonproductive cough. This prodromal phase was followed 1-10 days later by the development of a papular rash that typically progressed through stages of vesiculation, pustulation, umbilication and crusting. In some patients, early lesions have become ulcerated. Rash distribution and lesions have occurred on head, trunk and extremities; many of the patients had initial and satellite lesions on palms and soles and extremities. Rashes were generalized in some patients. After onset of the rash, patients have generally manifested rash lesions in different stages.
All patients reported direct or close contact with prairie dogs, most of which were sick. Illness in prairie dogs was frequently reported as beginning with a blepharo-conjunctivitis, progressing to presence of nodular lesions in some cases. Some prairie dogs have died from the illness, while others reportedly recovered.
In May, the prairie dogs were sold by a Milwaukee animal distributor to two pet shops in the Milwaukee area and during a pet "swap meet" (pets for sale or exchange) in northern Wisconsin. The Milwaukee animal distributor had obtained prairie dogs and a Gambian giant rat that was ill at the time from a northern Illinois animal distributor. It is unclear whether other retail outlets are involved. Investigations are under way to traceback the source of the prairie dogs and the Gambian giant rat and determine if distributors in other states might be involved. Animal species susceptible to monkeypox virus may include non-human primates, lagomorphs (rabbits) and some rodents.
On the basis of preliminary findings from this investigation, it appears that the primary route of transmission may be from infected prairie dogs to humans as a result of close contact. However, the possibility of human-to-human transmission cannot be excluded at this time. As a precaution until additional information is available, the measures below should be followed.
If a patient with suspect monkeypox infection is seen as an outpatient or admitted to the hospital, infection control personnel should be notified immediately. A combination of Standard, Contact, and Airborne Precautions http://www.cdc.gov/ncidod/hip/ISOLAT/Isolat.htm should be applied in all health care settings. These include:
Segregate the patient from others in the reception area as soon as possible, preferably in a private room with negative pressure relative to the surrounding area. Place a surgical mask over the patient's nose and mouth. Care should be taken to cover exposed skin lesions (sheet and/or gown on patient) to prevent contact with infectious material.
Veterinarians should use personal protective equipment, including gloves and gowns. When examining sick rodents, lagomorphs and exotic pets, especially prairie dogs and Gambian giant rats, a NIOSH-certified N95 filtering disposable respirator should be used, if available; otherwise, a surgical mask should be worn. When a suspect case is identified, veterinarians should limit staff that come in contact with the animal, and if the animal is admitted, it should be housed in a manner that would isolate it from all other animals. Housing in a negative air-flow room is highly recommended, if available.
No specific treatment recommendations are being made at this time. Smallpox vaccine has been reported to reduce the risk of monkeypox among previously vaccinated persons in Africa. CDC is assessing the potential role of postexposure use of smallpox vaccine as well as therapeutic use of cidofovir.
Health care providers, veterinarians and public health personnel should report cases of these illnesses in humans and animals to their state or local health departments as soon as they are suspected.
Procedures recommended for collection of samples for diagnosis of potential monkeypox disease are essentially the same as those for diagnosis of the related orthopoxvirus diseases, vaccinia and smallpox. For information regarding collection of serum specimens and lesions, please refer to the smallpox laboratory testing guidelines at http://www.bt.cdc.gov/agent/smallpox/lab-testing/index.asp. Consultation with the state epidemiologist (http://www.cste.org/members/state_and_territorial_epi.asp) and state health laboratory (http://www.aphl.org/public_health_labs/index.cfm) is necessary for submission instructions before sending specimens to CDC.
For more information contact your state or local health department or the CDC Emergency Operations Center (770) 488-7100. Additional information and recommendations will be released as they become available. Updated information will be available at http://www.cdc.gov.
Local, state, and federal agencies and private institutions that have participated in this investigation to date have included the Marshfield Clinic and Marshfield Laboratories, Froedtert Hospital and Medical College of Wisconsin, the City of Milwaukee Health Department, and at least 10 additional local health departments in Wisconsin and Illinois; the Wisconsin Division of Public Health, Wisconsin Department of Agriculture Trade and Consumer Protection, and Wisconsin State Laboratory of Hygiene; the Illinois Department of Public Health and the Illinois State Department of Agriculture; the Indiana Department of Health, and the US Department of Agriculture.
Respirators should be used in the context of a complete respiratory protection program in accordance with OSHA regulations. This includes training and fit testing to ensure a proper seal between the respirator's sealing surface and the wearer's face. Detailed information on respirator programs, including fit test procedures, can be accessed at http://www.osha.gov/SLTC/etools/respiratory. Where possible, a qualitative fit test should be conducted for N-95 respirators; detailed information on fit testing can be accessed at http://www.osha.gov/SLTC/etools/respiratory/oshafiles/fittesting1.html.